Freenome (FRNM) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$114,943.00

Net income growth (year over year)

−115.23%

Net margin

—

Return on equity

−1.99%

EPS (trailing twelve months)

−$0.07

Book value per share

$7.64

P/E (trailing twelve months)

—

Price to book

18.00

Debt to assets

8.25%

Payout ratio

—

Dividend yield

—

Company profile

Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection. It is developing a range of blood-based cancer screening tests.

• How do I buy stock in Freenome (FRNM)?

  FRNM trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.